ReviewInternational immunopharmacology2017
Interferon-omega: Current status in clinical applications.
Review in International immunopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Use of the Combination Therapy of Recombinant Feline Interferon-Omega Injection and Oral Prednisolone for Canine Aural Hematoma: A Retrospective Case Series.Veterinary sciences · 2026Article
- Non-specific Protein and Peptide Antibacterial Factors of Mammals.The protein journal · 2026Review
- Human interferon-ω: an underappreciated type I interferon.Frontiers in immunology · 2026Review
- Long-term efficacy of cyclosporine and interferon-ω in feline chronic gingivostomatitis: insights from SDAI scores.BMC veterinary research · 2025Article
- The association between single-nucleotide polymorphisms within type 1 interferon pathway genes and human immunodeficiency virus type 1 viral load in antiretroviral-naïve participants.AIDS research and therapy · 2024Article
- Chromosome-level genome provides insights into environmental adaptability and innate immunity in the common dolphin (delphinus delphis).BMC genomics · 2024Article
- Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis.Hepatology communications · 2024Article
- Long-Read Sequencing Reveals Rapid Evolution of Immunity- and Cancer-Related Genes in Bats.Genome biology and evolution · 2023Article
- Transcriptomic signatures of feline chronic gingivostomatitis are influenced by upregulated IL6.Scientific reports · 2023Article
- Molecular cloning, prokaryotic expression and its application potential evaluation of interferon (IFN)-ω of forest musk deer.Scientific reports · 2023Article
- Transcriptomic signatures of feline chronic gingivostomatitis are influenced by upregulated IL6.Research square · 2023Article
- Defining the characteristics of interferon-alpha-stimulated human genes: insight from expression data and machine learning.GigaScience · 2022Article
- Multidistrict Host-Pathogen Interaction during COVID-19 and the Development Post-Infection Chronic Inflammation.Pathogens (Basel, Switzerland) · 2022Review
- Isolation and characterization of the mink interferon-epsilon gene and its antiviral activity.Frontiers in veterinary science · 2022Article
- Feline Coronavirus and Alpha-Herpesvirus Infections: Innate Immune Response and Immune Escape Mechanisms.Animals : an open access journal from MDPI · 2021Review
- Forms and Methods for Interferon's Encapsulation.Pharmaceutics · 2021Review
- Therapeutic and Prophylactic Use of Oral, Low-Dose IFNs in Species of Veterinary Interest: Back to the Future.Veterinary sciences · 2021Review
- Clinical and Hematological Follow-Up of Long-Term Oral Therapy with Type-I Interferon in Cats Naturally Infected with Feline Leukemia Virus or Feline Immunodeficiency Virus.Animals : an open access journal from MDPI · 2020Article
- Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-ω Proteins.Viruses · 2020Article
- Influence of interferon-based drugs on immunological indices in specific prevention.Veterinary world · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many animals, but not canines and mice. It has been demonstrated to have antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.